Journal of Thoracic Disease · Sep 28, 2026

Geriatric-8 identifies patients at risk of early death in advanced non-small cell lung cancer: a single-center retrospective study

By Toriyama K, Imasato D, Kinoshita H et al.

BACKGROUND: Elderly patients with advanced lung cancer frequently experience declines in physical and cognitive function, which can complicate treatment decision-making. Although comprehensive geriatric assessment has been reported to support individualized dose adjustments and reduce treatment-related adverse events, its impact on prognosis remains unclear. The Geriatric-8 (G-8) is an eight-item geriatric screening tool, and we hypothesized that it may help detect vulnerabilities not captured by performance status (PS) alone and identify patients who may be unsuitable for chemotherapy. Therefore, we retrospectively investigated whether the G-8 score assessed prior to the initiation of chemotherapy could predict early mortality in elderly patients with advanced lung cancer who received chemotherapy. METHODS: A total of 22 patients aged 70 years or older with advanced non-small cell lung cancer without any actionable molecular-targeted therapies and good PS (0-1) who received treatment at our hospital between April 2024 and March 2026 were enrolled in this study. Early mortality was defined as death occurring within six months. A receiver operating characteristic curve was generated to identify the G-8 score that best discriminated between early- and non-early-death groups. Patients were subsequently divided into two groups according to this cutoff, and their median overall survival (OS) was compared. Univariate analyses were also performed to examine the association between the G-8 score and OS. RESULTS: Nineteen patients were categorized into Group A (G-8 score ≥12) and three into Group B (G-8 score <12). The median OS of Group B was significantly shorter than that of Group A [2.04 months (95% CI: 1.45-NR) vs. NR (95% CI: 8.28-NR); hazard ratio: 7.05; 95% CI: 1.53-32.3; P<0.05]. Univariate analysis of OS and the G-8 score showed a hazard ratio of 0.71 (95% CI: 0.55-0.91; P=0.007). CONCLUSIONS: The G-8 score may help identify the risk of early mortality in elderly patients with advanced non-small cell lung cancer who otherwise appear clinically well, particularly when used in combination with PS, offering greater discriminatory ability than PS alone.

doi.org/10.21037/jtd-2026-1566Open accessPubMed 42996972Biomarkers

AgingResearch.News